Our Work
Latham Secures Unconditional German and UK Clearances for Thermo Fisher Scientific’s US$3.1 Billion Planned Acquisition of Olink Holding
July 8, 2024
Deal complements Thermo Fisher’s existing life sciences and mass spectrometry offerings, accelerating protein biomarker discovery and providing strong synergy opportunities.
Latham’s antitrust team in London has today successfully secured Phase 1 unconditional CMA clearance for Thermo Fisher Scientific’s planned US$3.1 billion acquisition of Olink Holding. The firm also secured a Phase 2 unconditional clearance before the German Federal Cartel Office in June 2024.
Thermo Fisher is a world-class biotechnical company delivering innovative technologies, purchasing convenience, and pharmaceutical services, while Olink is a leading provider of next-generation proteomics solutions. The acquisition enhances Thermo Fisher’s capabilities in the high-growth proteomics market with the addition of highly differentiated solutions.
The Latham team (for the CMA investigation) was led by Antitrust & Competition partner Simon Pritchard, counsel Ludmilla Le Grand, with partner Greg Bonné, and associates James Mathieson, Nootan Vegad, and Jamie Mansour in London.
The team advising on the German Phase 2 investigation was led by Antitrust & Competition partners Sven Völcker in Brussels, Max Hauser in Frankfurt, and Anthemis Economou in Brussels, with support from associates Helena Hofmann in Frankfurt, Florence Eicher, and Julia Weber in Brussels. Counsel Philipp Studt in Brussels advised on the FDI aspects of the transaction.